文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

CT与MRI图像引导近距离放疗在局部晚期宫颈癌中的倾向评分匹配分析

CT versus MRI for Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: A Propensity Score-Matched Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-02-13

本研究纳入2016至2023年接受放化疗及CT-超声或MRI图像引导近距离放疗的FIGO(2018)IB3-IVA期宫颈癌患者,经倾向评分匹配后比较CT与MRI队列的局部控制、无病生存及不良事件。中位随访35.3个月,两组3年局部控制率和无病生存率均无显著差异,晚期≥3级胃肠及泌尿生殖毒性相当。结论提示CT引导近距离放疗可能提供与MRI相当的结局,但结果需前瞻性研究验证。

要点

  • 匹配后CT与MRI队列3年局部控制率分别为89%和92%,无病生存率分别为71%和73%,差异均无统计学意义。
  • 晚期≥3级胃肠毒性CT组8.2% vs MRI组11%(P=.51),泌尿生殖毒性2.5% vs 4.2%(P=.49)。
  • CT非劣效性风险比为0.84(95%CI 0.34-2.07),检验效能0.69,结果属假设生成性。

核心结论

  • 基于CT的近距离放疗可能提供与基于MRI的近距离放疗相当的结局。
  • 研究结果应视为假设生成,需前瞻性研究验证。

研究设计与样本

  • 纳入2016至2023年FIGO(2018)IB3-IVA期接受(放)化疗及CT-超声或MRI图像引导近距离放疗的患者。
  • 共689例患者,其中240例符合倾向评分匹配条件,CT和MRI队列各120例。
  • 计划目标为高危临床靶区D90≥85 Gy10,膀胱、直肠和乙状结肠2cc EQD2分别≤90 Gy3、≤75 Gy3和≤75 Gy3。
  • 采用倾向评分匹配比较局部控制、无病生存和不良事件,使用log-rank检验和Cox回归模型进行单变量和多变量分析。
  • 针对5%非劣效性界值进行事后效能分析,假设α=.15。

主要发现

  • 中位高危临床靶区体积为34 cc(IQR 26-42)。
  • 中位随访35.3个月,CT与MRI队列3年局部控制率分别为89%(95%CI 82%-97%)和92%(95%CI 87%-97%),P=.71。
  • 3年无病生存率分别为71%(95%CI 62%-82%)和73%(95%CI 65%-81%),P=.86。
  • 晚期≥3级胃肠毒性分别为8.2%和11%(P=.51),泌尿生殖毒性分别为2.5%和4.2%(P=.49)。

关键数值与推荐

  • 高危临床靶区D90计划目标≥85 Gy10。
  • 膀胱2cc EQD2≤90 Gy3,直肠2cc EQD2≤75 Gy3,乙状结肠2cc EQD2≤75 Gy3。
  • CT非劣效性风险比为0.84(95%CI 0.34-2.07),检验效能0.69。

临床怎么用

  • 在资源受限或MRI不可及时,CT引导近距离放疗可作为局部晚期宫颈癌的替代选择。
  • 实施CT引导近距离放疗时应遵循高危临床靶区D90≥85 Gy10及膀胱、直肠、乙状结肠2cc EQD2限值。
  • CT引导下可结合腔内-组织间插植技术处理高危临床靶区体积较大的患者。

局限性

  • 结果为假设生成性,需前瞻性研究验证。
  • 事后非劣效性检验效能为0.69,低于常规标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although MRI is the gold standard for image-guided brachytherapy for cervix cancer, CT scan is widely used. However, there is a dearth of comparative evidence. METHODS AND MATERIALS: Patients with FIGO (2018) stage IB3-IVA treated with (chemo)radiation and CT-ultrasound or MRI-based image-guided brachytherapy from 2016 to 2023 were included. The planning aim was to achieve D90 of ≥ 85 Gy10 to high-risk clinical target volume and ≤90 Gy3, ≤75 Gy3, and ≤75 Gy equivalent dose in 2 Gy (EQD2) to 2cc bladder, rectum, and sigmoid, respectively. Propensity score matching was performed to compare local control, disease-free survival, and adverse events. Univariate and multivariable analyses were performed using the log-rank test and the Cox regression model. Post hoc power analysis was performed for noninferiority margin of 5%, assuming α = .15. RESULTS: Of the 689 patients, 240 were eligible for propensity score matching (120 each in CT and MRI cohorts). Median high-risk clinical target volume was 34 cc (IQR, 26-42). Forty-three percent (n = 104) of patients underwent intracavitary-interstitial brachytherapy (IC-ISBT), whereas others received ICBT. At a median follow-up of 35.3 months, there was no difference in 3-year local control and disease-free survival between CT and MRI cohorts (local control, 89% [95% CI, 82%-97%] vs 92% [95% CI, 87%-97%], P = .71; disease-free survival, 71% [95% CI, 62%-82%] vs 73% [95% CI, 65%-81%], P = .86; respectively). Late grade ≥3 gastrointestinal and genitourinary toxicities were comparable ([8.2% vs 11%, P = .51] and [2.5 vs 4.2%, P = .49]). The hazard ratio for noninferiority of CT was 0.84 (95% CI, 0.34-2.07) with power of 0.69. CONCLUSIONS: CT-based brachytherapy may provide comparable outcomes to MRI-based BT. The results of the study should be considered hypothesis-generating needing validation in prospective studies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nagar A, Samanta A, Chopra S, et al. CT versus MRI for Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: A Propensity Score-Matched Analysis. Int J Radiat Oncol Biol Phys. 2026. PMID: 41692354. doi:10.1016/j.ijrobp.2026.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。